January 06, 2025 04:17 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bharatiya Janata Party releases first list of candidates for Delhi Assembly polls, fields Parvesh Sahib Singh Verma against Kejriwal | Firecracker unit explosion in Tamil Nadu's Virudhunagar kills 6 | Body of independent journalist, who went missing on Jan 1, found in a septic tank in Chhattisgarh | Delhi: 14-year-old student stabbed to death outside school after brawl with classmate | Rohit Sharma confirms he is not retiring amid speculations after skipping Sydney Test | India objects to China's 'new counties' announcement, says parts of these come under Ladakh | No cause for alarm over HMPV virus spread in China: Indian Health Agency | PM Modi gives a call for change in Delhi launching fierce attack on Arvind Kejriwal's AAP | Quran open to passage glorifying violence, bomb-making materials tracked in New Orleans attacker Shamshud-Din Jabbar's home | Jasprit Bumrah leads India in series decider after Rohit Sharma opts to rest in Sydney Test amid poor show with willow
Covaxin | Bharat Biotech
Image Credit: Pixabay

Bharat Biotech to start Covaxin trials in 2-18 age grp in next 10-12 days: Niti Aayog member

| @indiablooms | May 19, 2021, at 02:13 am

New Delhi/IBNS: Bharat Biotech will launch the phase II and III clinical trials for Covaxin in children between the ages of 2 to 18 years in the next 10-12 days,  Dr VK Paul, member (health) of Niti Aayog, said on Tuesday.

"Covaxin has been approved by the Drugs Controller General of India (DCGI), for Phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days," Paul said during a press conference, reported Hindustan Times.

On May 11, Drugs Controller General of India's (DCGI) gave its nod to conduct clinical trials in children.

DGCI gave the permission based on the recommendations by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation’s (CDSCO), which signalled the trial subject to certain conditions, the report said.

In February last, Bharat Biotech had approached the DGCI seeking permission for conducting clinical trials in children in the 5-18 age group.

However, the central drug regulator had rejected the proposal and asked the firm to come up with data showing the vaccine's efficacy in adults first.

The US and Canada have already approved the Pfizer-BioNTech shots for ages 12-15 and started vaccinating them from May 14.

Canada,too, had approved the Pfizer jabs for this age group on May 5.

Meanwhile, the European Medical Agency is also measuring the efficacy of the use of Pfizer vaccines in beneficiaries below 18 years of age.

The clinical trials in India are expected to be conducted in 525 participants at multiple hospitals, the HT report said.

AIIMS chief Dr Randeep Guleria had stated the need for quick data and risk-benefit analysis of the Covid-19 vaccine in children. 

Experts across the world have been appealing to the governments across the world to vaccinate children for the schools to reopen safely.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.